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Perioperative -blocker therapy in vascular
surgery: Clinical update
Daniel G. Hackam, MD, FRCPC,a,b,c,d Toronto, Ontario, Canada
Patients undergoing vascular surgery comprise a group at elevated risk of fatal and nonfatal perioperative cardiovascular
events. In four recent longitudinal studies, the 30-day incidence of death in such patients was 3% to 6%, and the incidence
of myocardial infarction was 5% to 14%. Growing evidence suggests that -adrenergic receptor antagonists prevent
cardiovascular morbidity and mortality in high-risk patients undergoing noncardiac surgery, including those undergoing
vascular surgery. This article reviews the available evidence concerning -blockers and provides guidance for their use in
the perioperative setting. (J Vasc Surg 2006;43:632-4.)Peripheral arterial disease and aortic aneurysms account
for 272,000 hospitalizations and 38,748 deaths in the
United States each year.1 Many patients with these condi-
tions undergo vascular surgery, and a substantial propor-
tion of them are at increased risk of perioperative cardio-
vascular events. For instance, four recent cohorts of patients
undergoing major vascular surgery or infrainguinal revas-
cularization had a 30-day mortality rate of 3% to 6% and a
30-day myocardial infarction rate of 5% to 14%.2-5
From the Division of Clinical Pharmacology & Toxicology, Sunnybrook &
Women’s College Health Sciences Centera; Institute for Clinical Evalua-
tive Sciences, University of Torontob; Cardiac Rehabilitation and Second-
ary Prevention Program, Toronto Rehabilitation Institutec; and Clinical
Epidemiology and Health Care Research Program, Department of Health
Policy, Management, and Evaluation, Faculty of Medicine, University of
Toronto.d
Conflict of interest: none.
Reprint requests: Dr Daniel Hackam, Room G157, Sunnybrook & Women’s
College Hospital, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5,
Canada (e-mail: daniel.hackam@ices.on.ca).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.12.014
Table I. Randomized trials of -blockers in vascular surge
Trial Sample and procedures
Poldermans12 112 patients; aortic or infrainguinal
surgery
Powell13 103 patients; infrarenal vascular
surgery
Raby14 26 patients; aortic, infrainguinal or
carotid surgery
Yang15 496 patients; aortic, infrainguinal or
extra-anatomic revascularization
MI, Myocardial infarction.
*Supplemented with intravenous metoprolol as needed.
632This situation has prompted the investigation of a
diverse array of therapies for preventing ischemic events in
patients scheduled for peripheral arterial or aortic recon-
structive surgeries. Approaches studied have included anti-
platelets, statins, -blockers, calcium-channel blockers,
-agonists, preoperative coronary revascularization, and
postoperative intensive monitoring. Of these approaches,
-blockers have received the lion’s share of recent atten-
tion. This article reviews the evidence concerning -block-
ers and provides recommendations for their use in patients
undergoing vascular surgery.
CLINICAL EVIDENCE
Randomized trials outside the operative setting dem-
onstrate that -blockers prevent coronary events and death
in patients with chronic heart failure, myocardial infarction,
or ventricular arrhythmias.6 Moreover, they reduce mor-
bidity in patients with angina or atrial fibrillation and pre-
vent arrhythmias following cardiac or thoracic surgery.7
Systematic reviews of randomized trials suggest -blockers
may also prevent ischemic events in patients undergoing
ith cardiovascular outcomes
tervention Findings
bisoprolol* 91% reduction in cardiac death or MI;
findings maintained at 2 years
metoprolol* No difference in cardiac events; hospital stay
3 days shorter in the metoprolol arm
lol infusion Only 2 cardiac events occurred
(1 per arm); postoperative ischemia on
Holter reduced by 54% (P  .05)
metoprolol* Nonsignificant 16% reduction in cardiac
events at 30 days (P  .40); longer-term
outcomes not yet reportedry w
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Volume 43, Number 3 Hackam 633noncardiac surgery.8-11 The largest and most comprehen-
sive of these reviews was recently published by Devereaux
et al.8
Devereaux et al pooled data from 22 trials of -blocker
treatment for noncardiac surgery, including six studies that
exclusively enrolled patients undergoing vascular surgery.
Overall, a statistically significant, sizeable reduction was
noted in the composite outcome of cardiovascular mortal-
ity, myocardial infarction, or cardiac arrest, with a relative
risk (RR) of 0.44 (95% confidence interval [CI], 0.20 to
0.97).8 Significance was not reached for the individual
components of this outcome, although favorable trends
were seen (eg, myocardial infarction had a RR of 0.40; 95%
CI, 0.14 to 1.15). On the other hand, -blockers were
associated with increases in certain adverse events, namely,
hypotension (RR, 1.27; 95% CI, 1.04 to 1.56) and brady-
cardia (RR, 2.27; 95% CI, 1.53 to 3.36). Consistent find-
ings have been noted in other systematic reviews.9-11 The
-blocker trials in vascular surgery that reported cardiac
outcomes are described in Table I.
The relative efficacy of perioperative -blockade may be
tied to baseline risk. In a very large propensity-matched
cohort study of 663,635 perioperative patients that in-
cluded 51,095 who underwent vascular surgery, -blocker
Table II. Lindenauer’s modification of the revised
cardiac risk index (RCRI)12
Criteria* Definition
High-risk surgery Intrathoracic, intraperitoneal, and
suprainguinal vascular procedures
Ischemic heart disease By history
Cerebrovascular disease By history
Renal insufficiency By history
Diabetes mellitus History of diabetes mellitus or
treatment with hypoglycemic
therapy
*Each criterion counts as one point towards the total RCRI score.
Table III. Perioperative -blocker therapy
Contraindications6:
Reactive airways disease, hypotension, bradycardia (heart rate 50
or intolerance, decompensated heart failure
Oral regimen:
Oral agents studied in vascular surgery patients are atenolol, bisop
surgery settings are labetalol, oxprenolol, timolol, and proprano
Start low-dose -blocker, such as atenolol (50 mg once daily), at
to 60 beats/min. In postoperative patients unable to take -blo
if blood pressure is 100 mm Hg or heart rate is 55 beats/m
postoperatively. Some evidence suggests that therapy continued
Intravenous regimen:
Intravenous agents studied in vascular surgery patients are esmolo
surgery settings are labetalol and atenolol.
A successfully trialed atenolol regimen with evidence of long-term
as two 5-mg aliquots over 5 minutes each (total of 10 mg). Imm
after surgery and each day thereafter until discharge, administer
atenolol (50 to 100 mg, orally) once daily. Titrate dose to achie
is 100 mm Hg before a scheduled dose, hold the -blocker.therapy was associated with benefit only in patients at
moderate-to-high perioperative risk, which was defined as a
revised cardiac risk index (RCRI) 2.16 Patients in the
lowest tiers of risk (RCRI 2) did not accrue any treat-
ment-related benefit (Table II). Although the study was
nonrandomized, these data do concur with the pooled
results from randomized trials in suggesting a benefit of
perioperative -blocker therapy in high-risk patients. Addi-
tional perioperative -blocker trials are ongoing. Another
interesting but unresolved question is whether -blockers
decrease the severity of perioperative myocardial infarc-
tion as assessed by the magnitude of elevated cardiac
biomarkers.
RECOMMENDATIONS
The available evidence supports the use of -blockers in
at-risk patients scheduled for noncardiac surgery, including
vascular surgery. Given their usual risk factor burdens,
comorbidity, and underlying atherosclerosis, many patients
undergoing major vascular surgery would be candidates for
-blocker therapy. Some evidence suggests that clinical
practice may be catching up to the evidence. In three recent
studies of patients undergoing vascular surgery, for in-
stance, the rates of perioperative -blocker use were 68%,3
85%,5 and 69%,17 respectively.
The -blocker regimens used in clinical trials vary
widely. It is likely that two variables are most important: the
consistent attainment of a -blocked heart rate and the use
of a long-acting agent.18 In elective cases, treatment should
be started at least 1 to 2 weeks before surgery and titrated to
achieve a heart rate of 60 beats/min. The -blocker
should ideally be continued for at least 30 days after sur-
gery, given the continued high risk throughout this inter-
val. In urgently admitted patients without contraindica-
tions, an alternative would be an intravenous -blocker.
Several effective regimens are summarized in Table III.
ond- or third-degree heart block (without a pacemaker), allergy
, and metoprolol. Other oral agents studied in noncardiac
to 2 weeks before surgery. Titrate to achieve a heart rate of 50
orally, administer an intravenous -blocker. Hold the -blocker
fore a scheduled dose. Continue therapy for at least 30 days
days is even more advantageous.14,19
metoprolol. Other intravenous agents studied in noncardiac
fit follows.20 Thirty minutes before surgery, administer atenolol
tely after surgery, repeat the same dose. Starting the morning
olol (10 mg, intravenously) every 12 hours or (preferably)
heart rate 65. If heart rate is 55 or the systolic blood pressure), sec
rolol
lol.
least 1
cker
in be
30
l and
bene
edia
aten
ve a
JOURNAL OF VASCULAR SURGERY
March 2006634 HackamREFERENCES
1. American Heart Association. Heart Disease and Stroke Statistics—2005
update. Dallas, Texas 2005.
2. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al;
BASIL trial participants. Bypass versus angioplasty in severe ischaemia of
the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;
366:1925-34.
3. Bursi F, Babuin L, Barbieri A, Politi L, Zennaro M, Grimaldi T, et al.
Vascular surgery patients: perioperative and long-term risk according to
the ACC/AHA guidelines, the additive role of post-operative troponin
elevation. Eur Heart J 2005;26:2448-56.
4. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L.
Risk factors, medical therapies and perioperative events in limb salvage
surgery: Observations from the PREVENT III multicenter trial. J Vasc
Surg 2005;42:456-64.
5. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F,
et al. Coronary-artery revascularization before elective major vascular
surgery. N Engl J Med 2004;351:2795-804.
6. Lopez-Sendo J, Swedberg K, McMurray J, Tamargo J, Maggioni AP,
Dargie H, et al. Expert consensus document on {beta}-adrenergic
receptor blockers: The Task Force on Beta-Blockers of the European
Society of Cardiology. Eur Heart J 2004;25:1341-62.
7. Sedrakyan A, Treasure T, Browne J, Krumholz H, Sharpin C, van der
MJ. Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia
in general thoracic surgery: evidence from randomized clinical trials.
J Thorac Cardiovasc Surg 2005;129:997-1005.
8. Devereaux PJ, Beattie WS, Choi PT, Badner NH, Guyatt GH, Villar JC,
et al. How strong is the evidence for the use of perioperative beta
blockers in non-cardiac surgery? Systematic review and meta-analysis of
randomised controlled trials. BMJ 2005;331:313-21.
9. Auerbach AD, Goldman L. Beta blockers and reduction of cardiac events in
noncardiac surgery: scientific review. JAMA 2002;287:1435-44.
10. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta
blockade: what is the actual risk reduction? Surgery 2005;138:171-9.11. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protec-
tion in patients undergoing noncardiac surgery: a quantitative system-
atic review. Anesth Analg 2003;97:623-33.
12. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LLM,
Blankensteijn JD, et al. The effect of bisoprolol on perioperative mor-
tality and myocardial infarction in high-risk patients undergoing vascu-
lar surgery. N Engl J Med 1999;341:1789-94.
13. Powell JT. Perioperative -blockade (Pobble) for patients undergoing
infrarenal vascular surgery: results of a randomized double-blind con-
trolled trial. J Vas Surg 2005;41:602-9.
14. Raby KE, Brull SJ, Timimi F, Akhtar S, Rosenbaum S, Naimi C, et al.
The effect of heart rate control on myocardial ischemia among high-risk
patients after vascular surgery. Anesth Analg 1999;88:477.
15. Yang H, Raymer K, Butler R, Parlow J, Roberts R. Metoprolol after
vascular surgery (MaVS). Can J Anesth 2004;51(suppl 1):A7.
16. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin
EM. Perioperative beta-blocker therapy and mortality after major non-
cardiac surgery. N Engl J Med 2005;353:349-61.
17. Henke PK, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajago-
palin S, et al. Patients undergoing infrainguinal bypass to treat athero-
sclerotic vascular disease are underprescribed cardioprotective medica-
tions: effect on graft patency, limb salvage, and mortality. J Vasc Surg
2004;39:357-65.
18. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in
elderly patients: population based, retrospective cohort study. BMJ
2005;331:932.
19. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven
LLM, et al. Bisoprolol reduces cardiac death and myocardial infarction
in high-risk patients as long as 2 years after successful major vascular
surgery. Eur Heart J 2001;22:1353-8.
20. Mangano DT, Layug EL, Wallace A, Tateo I, The Multicenter Study of
Perioperative Ischemia Research Group. Effect of atenolol on mortality
and cardiovascular morbidity after noncardiac surgery. N Engl J Med
1996;335:1713-21.Submitted Nov 29, 2005; accepted Dec 10, 2005.
